Market Overview

Allergan to Acquire MAP Pharmaceuticals for $25.00/Share

Share:
Related AGN
Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock
Wall Street's M&A Chatter From November 18-20
Shire Loses Ground To Allergan In Thanksgiving Week Dry-Eye Scripts (Investor's Business Daily)

Allergan (NYSE: AGN) and MAP Pharmaceuticals (NASDAQ: MAPP)
today jointly announced that they have entered into a definitive merger
agreement whereby Allergan will acquire 100% of the shares of MAP
Pharmaceuticals for a price of $25.00 per share. MAP Pharmaceuticals is
a biopharmaceutical company focused on developing and commercializing
new therapies in Neurology, including LEVADEX®, an orally inhaled drug
for the potential acute treatment of migraine in adults. LEVADEX® is
currently under review with the U.S. Food and Drug Administration (FDA).

The transaction, which has been unanimously approved by the boards of
directors of both companies, will be accomplished pursuant to a cash
tender offer followed by a second step merger. The per share cash

See full press release

Posted-In: News Guidance Management M&A

 

Related Articles (MAPP + AGN)

View Comments and Join the Discussion!